In December 2019, Teva settled with the Department of Justice (DOJ) for $54 million to resolve False Claims Act (FCA) allegations that, among other things, Teva induced physicians to write prescriptions for drugs that treat...more
When Riordan, Lewis & Haden Inc. (RLH), a private equity firm, found itself ensnared in a False Claims Act (FCA) litigation for its role in a prescription drug kickback scheme orchestrated by one of its portfolio companies,...more
12/11/2019
/ Best Practices ,
Board of Directors ,
Corporate Governance ,
Corporate Liability ,
Enforcement Actions ,
False Claims Act (FCA) ,
Health Care Providers ,
Kickbacks ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Portfolio Companies ,
Prescription Drugs ,
Private Equity Firms ,
Risk Management ,
Settlement ,
TRICARE
On May 2, 2019, a jury sitting in the District of Massachusetts convicted five senior executives of Insys Therapeutics, Inc. (Insys) with racketeering conspiracy in violation of Title 18, United States Code, Section 1962(d)....more
12/2/2019
/ Acquittals ,
Bribery ,
Controlled Substances Act ,
Criminal Conspiracy ,
Criminal Convictions ,
Criminal Prosecution ,
Department of Justice (DOJ) ,
Indictments ,
Motion for Judgment ,
Opioid ,
Pharmaceutical Industry ,
Physicians ,
Racketeering